From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

about

The Challenge for Development of Valuable Immuno-oncology Biomarkers.Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies.

P2860

Q46008297-700E432B-46ED-49EB-B071-49850B69110E Q50231313-760CA35C-BBD6-4556-A763-B3F51E0343EA

P2860

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Item

http://www.wikidata.org/entity/Q45952214

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

@en

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

@nl

type

Item

label

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

@en

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

@nl

prefLabel

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

@en

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

@nl

P1476

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

@en

P2093

Arta M Monjazeb

http://www.w3.org/2001/XMLSchema#string

Daphne Day

http://www.w3.org/2001/XMLSchema#string

Elad Sharon

http://www.w3.org/2001/XMLSchema#string

Eric H Rubin

http://www.w3.org/2001/XMLSchema#string

Gary L Rosner

http://www.w3.org/2001/XMLSchema#string

Marcus O Butler

http://www.w3.org/2001/XMLSchema#string

S Percy Ivy

http://www.w3.org/2001/XMLSchema#string

P2860

Drug development: Raise standards for preclinical cancer research

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Innate and adaptive immune cells in the tumor microenvironment

A modified toxicity probability interval method for dose-finding trials.

Nivolumab plus ipilimumab in advanced melanoma.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

P304

4980-4991

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1158/1078-0432.CCR-16-3064

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28864726

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5736967

http://www.w3.org/2001/XMLSchema#string

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

about

P2860

P2860

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932